A new risk stratification model for idiopathic pulmonary fibrosis could shift treatment from passive monitoring to active, goal-oriented care.

Regulatory officials have granted Molbreevi priority review and assigned a goal date of Aug. 22, 2026. If approved, Molbreevi will be priced between $400,000 and $500,000 per year.

Insufficient evidence exists to show efficacy of novel hypersensitivity pneumonitis therapies, indicating the need for clinical protocols.

Relapse rates over 3 years did not differ with glucocorticoid withdrawal vs maintenance among patients with stable SjD-ILD.

Cough sounds carry disease-specific acoustic signatures. By analysing these signatures using an AI-based algorithm, the ...

Background Lung function testing remains a cornerstone in the assessment and management of interstitial lung disease (ILD) patients. The clinical implications of the Global Lung function Initiative ...

Awareness and early identification of risk factors associated with progressive pulmonary fibrosis (PPF) are important for effective management and for limiting disease progression. PPF refers to a ...

Description: Kevin Davidson, M.D., FCCP, will provide an update on autoimmune pulmonary alveolar proteinosis, including the pathophysiology of this rare lung disease, signs and symptoms, diagnosis and ...

Even when treated adequately, pulmonary tuberculosis can lead to pulmonary sequelae. Patients treated for PTB between 2012 and 2016 answered a standardized questionnaire and underwent chest ...

Combined antifibrotic/pulmonary vasodilator therapy vs antifibrotics alone was significantly and independently tied to less death or LTx risk (HRs, 0.24 vs 0.93). The combination of antifibrotic and ...